欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (11): 1211-1215.

• 基础研究 • 上一篇    下一篇

灵仙新苷在Beagle犬体内的药动学及其绝对生物利用度研究

王大为1, 李峰2, 徐平2, 周磊2, 刘李2, 刘晓东2   

  1. 1江苏省中医药研究院,南京 210028,江苏;
    2中国药科大学药物代谢动力学重点实验室,南京 210009,江苏
  • 收稿日期:2012-07-27 修回日期:2012-10-24 发布日期:2012-12-04
  • 通讯作者: 刘晓东,通信作者,男,教授,研究方向:药代动力学。Tel: 025-83271006 E-mail: xdliu@cpu.edu.cn
  • 作者简介:王大为,男,博士,主管药师,研究方向:药代动力学。Tel: 025-85608661 E-mail: cleverwdw@126.com
  • 基金资助:
    国家十一五新药创制重大专项基金 (2009ZX09103-371); 江苏省中医药局项目 (LB09059); 康缘中医药科技创新基金项目 (HZ1014KY)

Pharmacokinetics of clematichinenoside AR and its absolute bioavailability in Beagle dogs

WANG Da-wei1, LI Feng2, XU Ping2, ZHOU Lei2, LIU Li2, LIU Xiao-dong2   

  1. 1Jiangsu Provincial Academy of Traditional Chinese Medicine, Nanjing 210028, Jiangsu,China;
    2Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, Jiangsu, China
  • Received:2012-07-27 Revised:2012-10-24 Published:2012-12-04

摘要: 目的: 研究灵仙新苷在 Beagle犬体内的药动学和绝对生物利用度。方法: 采用四周期交叉设计,即 Beagle犬 8只,雌雄各半,随机等分为4组,分别采取单剂量静脉注射 (0.75 mg/kg)及灌胃 (7.5、15和 30 mg/kg)两种给药方式,交叉给药,间隔 1周。并于给药后不同时间点取血,采用 LC-MS/MS测定血浆中灵仙新苷的浓度,利用DAS 2.0 软件估算灵仙新苷在 Beagle犬体内的药动学参数,并计算绝对生物利用度。结果: Beagle犬i.g. 7.5、15和 30 mg/kg 灵仙新苷后,估算的 t1/2分别为 (14.3±2.7)、(13.3±1.3)和 (13.7±2.4) h,AUC0-36分别为(1.9±1.2)、(4.5±1.9)和 (8.0±3.3) μg·h·mL-1,Cmax分别为(0.14±0.08)、(0.27±0.10)和 (0.52±0.28) μg/mL。i.v. 0.75 mg/kg 灵仙新苷后,估算的 t1/2为 (13.3±3.0) h,AUC0-36为 (66.2±12.8) μg·h·mL-1。灌胃灵仙新苷在 Beagle犬体内的绝对生物利用度分别为 0.32%、0.35%和 0.30%。结论: 口服灵仙新苷后在 Beagle犬体内绝对生物利用度很低,其药动学过程在研究剂量范围内是线性的。

关键词: 灵仙新苷, LC-MS/MS, 药动学, 绝对生物利用度, Beagle犬

Abstract: AIM: To investigate the pharmacokinetics and absolute bioavailability of clematichinenoside AR (C-AR) in Beagle dogs. METHODS: By applying four cycle crossover design, a single dose of C-AR was administrated (i.v. 0.75 mg/kg or i.g. 7.5, 15 or 30 mg/kg) to 8 Beagle dogs.Blood samples were collected before and at different intervals after C-AR administration. The concentration of C-AR in dog plasma was determined by LC-MS/MS method.The pharmacokinetic parameters were estimated by DAS 2.0 pharmacokinetic program,and the absolute bioavailability was calculated.RESULTS: After single dose ig of 7.5, 15 and 30 mg/kg C-AR, the pharmacokinetics parameters were estimated as follows: t1/2: (14.3±2.7), (13.3±1.3) and (13.7±2.4) h; AUC0-36: (1.9±1.2), (4.5±1.9) and (8.0±3.3) μg·h·mL-1; Cmax: (0.14±0.08), (0.27±0.10) and (0.52±0.28) μg/mL. After single dose i.v. of 0.75 mg/kg C-AR, the pharmacokinetics parameters were estimated as follows: t1/2: (13.3±3.0) h,AUC0-36:(66.2±12.8) μg·h·mL-1. The absolute bioavailability of C-AR following i.g. administration was 0.32%, 0.35% and 0.30%. CONCLUSION: The absolute bioavailability of C-AR in dogs is low, and the pharmacokinetic properties were linear in Beagle dogs.

Key words: Clematichinenoside AR, LC-MS/MS, Pharmacokinetics, Absolute bioavailability, Beagle dog

中图分类号: